Therapeutic Areas

Progenra is focused on small molecule and molecular glue drug discovery; screening of small-molecule libraries and natural product extract collections has yielded potent inhibitors and activators of ubiquitin proteasome system therapeutic targets  associated with various diseases including neurodegenerative diseases such as Parkinson’s as Alzheimer’s, metabolic diseases,  cardiovascular disease and inflammatory diseases.

Molecular Glues for Neurodegenerative Diseases

Lewy Body Dementia Age of Onset, Lewy Body and Sleep, Parkinson's –  Dementia Aide

Neurodegenerative diseases: aging of the brain

Targeting mitophagy and protein aggregation

Dysfunction in the protein and organelle degradation system is believed to underlie most forms of neurodegenerative disease. In Alzheimer’s disease and Parkinson’s disease, protein aggregation, in conjunction with accumulation of defective mitochondria, leads to neuronal death. Progenra is developing molecular glues and PROTAC drug candidates that promote mitophagy and reduce pathogenic protein aggregation. Small molecules discovered by Progenra constitute a breakthrough MOA and a novel approach to treating neurodegenerative diseases.

Targeted degradation of aggregated Tau proteins

Accumulation of aggregated tau proteins is a hallmark of Alzheimer’s disease and several other neurodegenerative diseases. Tau protein aggregation, in conjunction with mitochondrial dysfunction, leads to neuronal death and neuronal inflammation. Progenra has developed small molecule drug candidates that specifically promote ubiquitination, degradation and clearance of pathogenic tau protein aggregates. Small molecules discovered by Progenra constitute novel approach to treating Alzheimer’s disease.

Cardiovascular Diseases

Defective mitophagy due to a failure in clearing the damaged mitochondria is linked heart failure. Progenra has developed novel small molecule enhancers of mitophagy by promoting Parkin E3 ubiquitin ligase activity. In addition to promoting mitophagy, these molecules promotes mitobiogenesis and improves mitochondrial function. Our lead compound showed therapeutic efficacy in  mouse models of heart failure.

Inflammatory Diseases

Inflammatory signal pathways are regulated at various points by E3 ligases. Progenra has developed Molecular Glue compounds that show in vivo anti-inflammatory activity in psoriasis and asthma models that is currently in preclinical development. We are also developing novel Molecular Glues (MGs) and PROTACs against proinflammatory target proteins for advancing them as anti-inflammatory agents.